24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.

Trial Details

NCT ID
NCT07043270
Phase
PHASE2
Sponsor
Dartmouth-Hitchcock Medical Center
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Nab-paclitaxel + Gemcitabine
  • modified FOLFIRINOX (mFOLFIRINOX)
Locations (sample)
  • Lebanon, New Hampshire, United States|43.64229,-72.25176

Key Eligibility Criteria

  • Age ≥ 18 years
  • Diagnosis of BR-PDAC. The resectability should be officially determined with surgical oncologists at the Dartmouth Cancer Center (DCC) GI multidisc…
  • Patients must be able and willing to provide informed consent.
  • Contrast-enhanced CT scan of the chest, abdomen, and pelvis performed within 45 days before registration.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →